Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

  1. Alvarez-Larrán, A.
  2. Garrote, M.
  3. Ferrer-Marín, F.
  4. Pérez-Encinas, M.
  5. Mata-Vazquez, M.I.
  6. Bellosillo, B.
  7. Arellano-Rodrigo, E.
  8. Gómez, M.
  9. García, R.
  10. García-Gutiérrez, V.
  11. Gasior, M.
  12. Cuevas, B.
  13. Angona, A.
  14. Gómez-Casares, M.T.
  15. Martínez, C.M.
  16. Magro, E.
  17. Ayala, R.
  18. del Orbe-Barreto, R.
  19. Pérez-López, R.
  20. Fox, M.L.
  21. Raya, J.-M.
  22. Guerrero, L.
  23. García-Hernández, C.
  24. Caballero, G.
  25. Murillo, I.
  26. Xicoy, B.
  27. Ramírez, M.J.
  28. Carreño-Tarragona, G.
  29. Hernández-Boluda, J.C.
  30. Pereira, A.
  31. Show all authors +
Journal:
Cancer

ISSN: 1097-0142,  0008-543X

Year of publication: 2022

Volume: 128

Issue: 13

Pages: 2441-2448

Type: Article

DOI: 10.1002/CNCR.34195 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus